Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6years with Hunter syndrome

Molecular Genetics and Metabolism

Volumn 114, Issue 2, 2015, Pages 156-160

  Sohn, Young Bae ^a   Cho, Sung Yoon ^b   Lee, Jieun ^b   Kwun, Yonghee ^b   Huh, Rimm ^b   Jin, Dong Kyu ^b  

^a Ajou University Medical CentSuwon   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Children; Enzyme replacement therapy; Hunter syndrome; Idursulfase beta; Mucopolysaccharidosis II

Indexed keywords

CREATINE; CREATININE; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; ANTIBODY;

ARTICLE; BODY HEIGHT; BODY WEIGHT; BRONCHITIS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME ACTIVITY; ENZYME REPLACEMENT; GASTROENTERITIS; HEAD CIRCUMFERENCE; HUMAN; HUNTER SYNDROME; MALE; OTITIS MEDIA; PHENOTYPE; PRIORITY JOURNAL; RHINORRHEA; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MUCOPOLYSACCHARIDOSIS II; PRESCHOOL CHILD; SOUTH KOREA; TREATMENT OUTCOME; URINE;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; GLYCOSAMINOGLYCANS; HUMANS; IDURONATE SULFATASE; INFANT; MALE; MUCOPOLYSACCHARIDOSIS II; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 84921630826     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2014.08.009     Document Type: Article

References (23)

1. The Metabolic and Molecular Basis of Inherited Disease 2001, McGraw-Hill, New York. 8th edition. F.N.M.J. Neufeld (Ed.).
2. Martin R., Beck M., Eng C., Giugliani R., Harmatz P., Munoz V., Muenzer J. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008, 121:e377-e386.
3. Wraith J.E., Scarpa M., Beck M., Bodamer O.A., De Meirleir L., Guffon N., Meldgaard Lund A., Malm G., Van der Ploeg A.T., Zeman J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 2008, 167:267-277.
4. Sohn Y.B., Cho S.Y., Park S.W., Kim S.J., Ko A.R., Kwon E.K., Han S.J., Jin D.K. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J. Rare Dis. 2013, 8:42.
5. Nakamura K., Hattori K., Endo F. Newborn screening for lysosomal storage disorders. Am. J. Med. Genet. C: Semin. Med. Genet. 2011, 157C:63-71.
6. Ruijter G.J., Goudriaan D.A., Boer A.M., Van den Bosch J., Van der Ploeg A.T., Elvers L.H., Weinreich S.S., Reuser A.J. Newborn Screening for Hunter Disease: A Small-Scale Feasibility Study JIMD reports 2013.
7. Tomatsu S., Fujii T., Fukushi M., Oguma T., Shimada T., Maeda M., Kida K., Shibata Y., Futatsumori H., Montano A.M., Mason R.W., Yamaguchi S., Suzuki Y., Orii T. Newborn screening and diagnosis of mucopolysaccharidoses. Mol. Genet. Metab. 2013, 110:42-53.
8. Furujo M., Kubo T., Kosuga M., Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI. Mol. Genet. Metab. 2011, 104:597-602.
9. McGill J.J., Inwood A.C., Coman D.J., Lipke M.L., de Lore D., Swiedler S.J., Hopwood J.J. Enzyme replacement therapy for mucopolysaccharidosis VI from 8weeks of age - a sibling control study. Clin. Genet. 2010, 77:492-498.
10. Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol. Genet. Metab. 2014, 111:63-72.
11. National Cancer Institute Common terminology criteria for adverse events v4.0. NIH Publication #09-7473 2009.
12. Lampe C., Atherton A., Burton B.K., Descartes M., Giugliani R., Horovitz D.D., Kyosen S.O., Magalhaes T.S., Martins A.M., Mendelsohn N.J., Muenzer J., Smith L.D. Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age JIMD Reports 2014.
13. Giugliani R., Hwu W.L., Tylki-Szymanska A., Whiteman D.A., Pano A. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet. Med. Off. J. Am. Coll. Med. Genet. 2014, 16:435-441.
14. Chung Y.K., Sohn Y.B., Sohn J.M., Lee J., Chang M.S., Kwun Y., Kim C.H., Lee J.Y., Yook Y.J., Ko A.R., Jin D.K. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj. J. 2014, 31:309-315.
15. Nii E., Urawa M., Nshimura T., Kitou H., Ikegawa S., Shimizu S., Taneda H., Uchida A., Niikawa N. Acrodysostosis with unusual iridal color changing with age. Am. J. Med. Genet. B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet. 2007, 144B:824-825.
16. Frankenburg W.K., Dodds J., Archer P., Shapiro H., Bresnick B. The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 1992, 89:91-97.
17. Schwartz I.V., Ribeiro M.G., Mota J.G., Toralles M.B., Correia P., Horovitz D., Santos E.S., Monlleo I.L., Fett-Conte A.C., Sobrinho R.P., Norato D.Y., Paula A.C., Kim C.A., Duarte A.R., Boy R., Valadares E., De Michelena M., Mabe P., Martinhago C.D., Pina-Neto J.M., Kok F., Leistner-Segal S., Burin M.G., Giugliani R. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta paediatrica (Oslo, Norway: 1992) 2007, Supplement 96:63-70.
18. Wraith J.E., Beck M., Giugliani R., Clarke J., Martin R., Muenzer J. Initial report from the Hunter Outcome Survey. Genet. Med. Off. J. Am. Coll. Med. Genet. 2008, 10:508-516.
19. Young I.D., Harper P.S. Mild form of Hunter's syndrome: clinical delineation based on 31 cases. Arch. Dis. Child. 1982, 57:828-836.
20. Young I.D., Harper P.S. The natural history of the severe form of Hunter's syndrome: a study based on 52 cases. Dev. Med. Child Neurol. 1983, 25:481-489.
21. Rozdzynska A., Tylki-Szymanska A., Jurecka A., Cieslik J. Growth pattern and growth prediction of body height in children with mucopolysaccharidosis type II. Acta paediatrica (Oslo, Norway: 1992) 2011, 100:456-460.
22. Cho S.Y., Huh R., Chang M.S., Lee J., Kwun Y., Maeng S.H., Kim S.J., Sohn Y.B., Park S.W., Kwon E.K., Han S.J., Jung J., Jin D.K. Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome). J. Korean Med. Sci. 2014, 29:254-260.
23. Schulze-Frenking G., Jones S.A., Roberts J., Beck M., Wraith J.E. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J. Inherit. Metab. Dis. 2011, 34:203-208.